{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:34Z","timestamp":1790755654304,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T00:00:00Z","timestamp":1602374400000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jbspin.2019.01.013","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T06:25:23Z","timestamp":1549002323000},"page":"568-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Strategy for suspected myositis"],"prefix":"10.1016","volume":"86","author":[{"given":"Alain","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2019.01.013_bib0005","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0010","article-title":"Muscle endurance deficits in myositis patients despite normal manual muscle testing scores","author":"Amici","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1212\/WNL.0000000000004061","article-title":"Physical activity monitoring: a promising outcome measure in idiopathic inflammatory myopathies","volume":"89","author":"Bachasson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0020","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/archneurol.2011.1728","article-title":"Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome","volume":"69","author":"Suzuki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0025","first-page":"1350","article-title":"Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis","volume":"15","author":"Needham","year":"2008","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/01.wnl.0000254503.91471.f5","article-title":"Muscle biopsy in patients with myalgia: still a painful decision","volume":"68","author":"Kissel","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0035","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0040","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0045","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00401-017-1731-9","article-title":"IFN-\u03b2-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis","volume":"134","author":"Meyer","year":"2017","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ahj.2007.06.008","article-title":"Distribution of creatine kinase in the general population: implications for statin therapy","volume":"154","author":"Brewster","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1468-1331.2010.03012.x","article-title":"EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia","volume":"17","author":"Kyriakides","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0060","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0065","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0070","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jbspin.2014.01.005","article-title":"An arthro-dermato-pulmonary syndrome associated with anti-MDA5 antibodies","volume":"81","author":"Goussot","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbspin.2017.03.005","article-title":"Inflammatory myopathies: a new landscape. - PubMed - NCBI","volume":"85","author":"Meyer","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0080","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/keu404","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lef\u00e8vre","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11926-013-0359-6","article-title":"Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis","volume":"15","author":"Kiely","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0090","doi-asserted-by":"crossref","first-page":"h6819","DOI":"10.1136\/bmj.h6819","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0095","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0139-2017","article-title":"State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances","author":"Sambataro","year":"2018","journal-title":"Eur Respir Rev Off J Eur Respir Soc"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0105","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/rheumatology\/kev192","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/ dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0125","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: A New Classification of Adult Autoimmune Myositis","volume":"69","author":"Sen\u00e9cal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0135","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-1-4160-2593-1.50007-3","article-title":"Histological and histochemical stains and reactions","author":"Dubowitz","year":"2007","journal-title":"Muscle Biopsy: A Pract Approach"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0145","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/BOR.0000000000000101","article-title":"Myositis mimics: how to recognize them","volume":"26","author":"Hilton-Jones","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0150","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0155","first-page":"S295","article-title":"Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls","volume":"20","author":"May","year":"2000","journal-title":"Radiogr Rev Publ Radiol Soc N Am Inc"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0160","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","article-title":"Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis","volume":"50","author":"Cox","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0165","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.39798","article-title":"Brief report: Power Doppler ultrasonography for detection of increased vascularity in the fascia: A potential early diagnostic tool in fasciitis of dermatomyositis: PDUS for detection of dermatomyositis-associated fasciitis","volume":"68","author":"Yoshida","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0170","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumdis-2016-210198","article-title":"Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity","volume":"76","author":"Pinal-Fernandez","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0175","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/annrheumdis-2012-202915","article-title":"Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis","volume":"73","author":"Malattia","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jbspin.2015.08.011","article-title":"Muscle MRI: All that glitters is not myositis","volume":"83","author":"Meyer","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0185","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0190","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0195","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0200","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0205","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/MD.0000000000000523","article-title":"In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome","volume":"94","author":"Meyer","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0210","doi-asserted-by":"crossref","first-page":"e4713","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0215","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/rheumatology\/41.9.1040","article-title":"Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome","volume":"41","author":"Coppo","year":"2002","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0220","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/rheumatology\/31.12.811","article-title":"Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients","volume":"31","author":"Lundberg","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0225","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjd.12564","article-title":"Meta-analysis of the association of dermatomyositis and polymyositis with cancer","volume":"169","author":"Wang","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","article-title":"Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study","volume":"77","author":"Dobloug","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0235","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0240","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0245","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/rheumatology\/kev247","article-title":"High incidence of cancer in anti-small ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis","volume":"54","author":"Muro","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0250","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1111\/j.1468-1331.2010.03220.x","article-title":"Screening for tumours in paraneoplastic syndromes: report of an EFNS task force","volume":"18","author":"Titulaer","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0255","series-title":"Dermatomyosite de l'enfant et de l'adulte","first-page":"110","author":"Bader-Meunier","year":"2016"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0260","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/key031","article-title":"Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies","volume":"57","author":"Lilleker","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0265","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4065\/82.4.441","article-title":"Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients","volume":"82","author":"Oh","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0270","first-page":"461","article-title":"Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study","volume":"55","author":"Rai","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0275","article-title":"The risk of ischemic and haemorrhagic stroke in idiopathic inflammatory myopathies: a Swedish population-based cohort study","author":"Svensson","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0280","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kex465","article-title":"Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample","volume":"57","author":"Silverberg","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0285","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/annrheumdis-2014-205800","article-title":"Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study","volume":"75","author":"Carruthers","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0290","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/rheumatology\/keq279","article-title":"Infections in polymyositis and dermatomyositis: analysis of 192 cases","volume":"49","author":"Chen","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0295","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1756-185X.13255","article-title":"Opportunistic infections in patients with idiopathic inflammatory myopathies","volume":"21","author":"Redondo-Benito","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis: ACR RA treatment recommendations","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0305","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12020-015-0756-x","article-title":"Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score","volume":"52","author":"CW-S","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0310","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/1756-185X.13257","article-title":"Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis","volume":"21","author":"Gupta","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0315","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/1756-185X.12405","article-title":"Prevalence and associated factors of reduced bone mineral density in patients with idiopathic inflammatory myopathies","volume":"19","author":"So","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0320","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","article-title":"Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies","volume":"24","author":"Alexanderson","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0325","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0330","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0335","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar3704","article-title":"Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine","volume":"14","author":"Schiopu","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0340","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-011-1840-0","article-title":"Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases","volume":"30","author":"Yu","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0345","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0350","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0355","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of Myositis-Related Interstitial Lung Disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0360","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0365","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0370","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0375","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0380","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.autrev.2017.07.016","article-title":"How I treat idiopathic patients with inflammatory myopathies in the clinical practice","volume":"16","author":"Cavagna","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0385","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0390","doi-asserted-by":"crossref","first-page":"A80-1","DOI":"10.1136\/ard.2010.149013.31","article-title":"Anakinra effects on T cells in patients with refractory idiopathic inflammatory myopathies","volume":"70","author":"Zong","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0395","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","article-title":"Therapeutic effect of tocilizumab on two patients with polymyositis","volume":"50","author":"Narazaki","year":"2011","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0400","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0405","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","author":"Kurasawa","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0410","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jbspin.2019.01.013_bib0415","first-page":"5L","article-title":"Rapamycin vs. placebo for the treatment of inclusion body myositis: improvement of the 6 min walking distance, a functional scale, the FVC and muscle quantitative MRI","volume":"69","author":"Benveniste","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19300119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19300119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:25:29Z","timestamp":1761150329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X19300119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1297319X19300119"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.013","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategy for suspected myositis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}]}}